Mixed versus pure variants of desmoplastic melanoma: A genetic and immunohistochemical appraisal

Modern Pathology

Volumn 25, Issue 4, 2012, Pages 505-515

  Miller, Daniel D ^a   Emley, Andrew ^a   Yang, Shi ^a   Richards, Joanna E ^a   Lee, Jung Eun ^a   Deng, April ^b   Hoang, Mai P ^c   Mahalingam, Meera ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

BRAF; CD117; desmoplasia; DNA sequencing; KIT; melanoma; RET

Indexed keywords

CLUSTERIN; KI 67 ANTIGEN; NESTIN; PROTEIN RET; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR SOX10;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DESMOPLASTIC MELANOMA; DNA SEQUENCE; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIXED TUMOR; PRIORITY JOURNAL; TUMOR GROWTH;

ADOLESCENT; AGED; AGED, 80 AND OVER; BOSTON; CELL PROLIFERATION; CLUSTERIN; FEMALE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERMEDIATE FILAMENT PROTEINS; KI-67 ANTIGEN; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASMS, COMPLEX AND MIXED; NERVE TISSUE PROTEINS; PHENOTYPE; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; PROTO-ONCOGENE PROTEINS C-RET; RECEPTORS, NERVE GROWTH FACTOR; SEQUENCE ANALYSIS, DNA; SKIN NEOPLASMS; SOXE TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859422429     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.196     Document Type: Article

References (45)

1. Feng Z, Wu X, Chen V, et al. Incidence and survival of desmoplastic melanoma in the United States, 1992-2007. J Cutan Pathol 2011;38:616-624.
2. Conley J, Lattes R, Orr W. Desmoplastic malignant melanoma. Cancer 1971;28:914-916.
3. Baer SC, Schultz D, Synnestvedt M, et al. Desmoplasia and neurotropism. Prognostic variables in patients with stage I melanoma. Cancer 1995;76:2242-2247.
4. George E, McClain SE, Slingluff CL, et al. Subclassification of desmoplastic melanoma: pure and mixed variants have significantly different capacities for lymph node metastasis. J Cutan Pathol 2009;36:425-432.
5. Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 2003;3:559-570. (Pubitemid 37328828)
6. Chudnovsky Y, Adams AE, Robbins PB, et al. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet 2005;37: 745-749. (Pubitemid 41754892)
7. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954. (Pubitemid 34716871)
8. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000. (Pubitemid 35424092)
9. Davison JM, Rosenbaum E, Barrett TL, et al. Absence of V599E BRAF mutations in desmoplastic melanomas. Cancer 2005;103:788-792. (Pubitemid 40216408)
10. Narita N, Tanemura A, Murali R, et al. Functional RET G691S polymorphism in cutaneous malignant melanoma. Oncogene 2009;28:3058-3068.
11. Busam KJ, Zhao H, Coit DG, et al. Distinction of desmoplastic melanoma from non-desmoplastic melanoma by gene expression profiling. J Invest Dermatol 2005;124:412-419. (Pubitemid 40175890)
12. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-4346. (Pubitemid 46630793)
13. Fusi A, Reichelt U, Busse A, et al. Expression of the stem cell markers nestin and CD133 on circulating melanoma cells. J Invest Dermatol 2011;131:487-494.
14. Ramos-Herberth FI, Karamchandani J, Kim J, et al. SOX10 immunostaining distinguishes desmoplastic melanoma from excision scar. J Cutan Pathol 2010;37: 944-952.
15. Civenni G, Walter A, Kobert N, et al. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res 2011;71:3098-3109.
16. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182: 311-322. (Pubitemid 30054364)
17. Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004;64:5913-5919. (Pubitemid 39129383)
18. Torres-Cabala CA, Wang WL, Trent J, et al. Correlation between KIT expression and KIT mutation in melanoma: A study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 2009;22: 1446-1456.
19. Kapur P, Selim MA, Roy LC, et al. Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis. Mod Pathol 2005;18:197-204. (Pubitemid 40188626)
20. Busam KJ, Mujumdar U, Hummer AJ, et al. Cutaneous desmoplastic melanoma: reappraisal of morphologic heterogeneity and prognostic factors. Am J Surg Pathol 2004;28:1518-1525. (Pubitemid 39425520)
21. Busam KJ. Cutaneous desmoplastic melanoma. Adv Anat Pathol 2005;12:92-102. (Pubitemid 40515797)
22. Soares de Almeida L, Requena L, Rutten A, et al. Desmoplastic malignant melanoma: a clinicopathologic analysis of 113 cases. Am J Dermatopathol 2008;30: 207-215.
23. Quinn MJ, Crotty KA, Thompson JF, et al. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer 1998;83:1128-1135. (Pubitemid 28419065)
24. Murali R, Shaw HM, Lai K, et al. Prognostic factors in cutaneous desmoplastic melanoma. Cancer 2010;116: 4130-4138.
25. Pawlik TM, Ross MI, Prieto VG, et al. Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer 2006;106:900-906. (Pubitemid 43238458)
26. Hawkins WG, Busam KJ, Ben-Porat L, et al. Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Oncol 2005;12:207-213. (Pubitemid 40568907)
27. Maurichi A, Miceli R, Camerini T, et al. Pure desmoplastic melanoma: a melanoma with distinctive clinical behavior. Ann Surg 2010;252:1052-1057.
28. Murali R, Zannino D, Synnott M, et al. Clinical and pathological features of metastases of primary cutaneous desmoplastic melanoma. Histopathol 2011;58:886-895.
29. Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 2001;12: 361-373. (Pubitemid 32851748)
30. Sawai H, Okada Y, Kazanjian K, et al. The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res 2005;65:11536-11544. (Pubitemid 41821712)
31. North J. CD117 (c-KIT) staining in desmoplastic melanoma. J Cutan Pathol 2011;38:753-755.
32. Winnepenninckx V, De Vos R, Stas M, et al. New phenotypical and ultrastructural findings in spindle cell (desmoplastic/neurotropic) melanoma. Appl Immunohistochem Mol Morphol 2003;11:319-325. (Pubitemid 37522682)
33. Lens MB, Newton-Bishop JA, Boon AP. Desmoplastic malignant melanoma: a systematic review. Br J Dermatol 2005;152:673-678. (Pubitemid 40571298)
34. Egbert B, Kempson R, Sagebiel R. Desmoplastic malignant melanoma. A clinicohistopathologic study of 25 cases. Cancer 1988;62:2033-2041. (Pubitemid 18261833)
35. Carlson JA, Dickersin GR, Sober AJ, et al. Desmoplastic neurotropic melanoma. A clinicopathologic analysis of cases. Cancer 1995;75:478-494.
36. Kong Y, Si L, Zhu Y, et al. Large-scale analysis of KIT alterations in Chinese patients with melanoma. Clin Cancer Res 2011;17:1684-1691.
37. Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14:6821-6828.
38. Park E, Yang S, Emley A, et al. Lack of correlation between immunohistochemical expression of CKIT and KIT mutations in atypical acral nevi. Am J Dermatopathol; advance online publication, 15 November 2011 (e-pub ahead of print).
39. Sihto H, Sarlomo-Rikala M, Tynninen O, et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol 2005;23:49-57. (Pubitemid 41702622)
40. Busam KJ, Kucukgol D, Eastlake-Wade S, et al. Clusterin expression in primary and metastatic melanoma. J Cutan Pathol 2006;33:619-623. (Pubitemid 44370059)
41. Henrique R, Azevedo R, Bento MJ, et al. Prognostic value of Ki-67 expression in localized cutaneous malignant melanoma. J Am Acad Dermatol 2000;43:991-1000.
42. Shimada S, Tsuzuki T, Kuroda M, et al. Nestin expression as a new marker in malignant peripheral nerve sheath tumors. Pathol Int 2007;57:60-67.
43. Cook AL, Smith AG, Smit DJ, et al. Co-expression of SOX9 and SOX10 during melanocytic differentiation in vitro. Exp Cell Res 2005;308:225-235.
44. Flamminger A, Besch R, Cook AL, et al. SOX9 and SOX10 but not BRN2 are required for nestin expression in human melanoma cells. J Invest Dermatol 2009;129:945-953.
45. Brychtova S, Fluraskova M, Hlobilkova A, et al. Nestin expression in cutaneous melanomas and melanocytic nevi. J Cutan Pathol 2007;34:370-375. (Pubitemid 46633338)